BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2014-08-08
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2014-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2014-03-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2013-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2013-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2013 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month |
|---|---|---|---|---|
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | $0.00 derived: sum of 3 quarters · filed 2014-08-08 | $0.00 derived: sum of 4 quarters · filed 2014-08-08 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 | $0.00 derived: sum of 2 quarters · filed 2014-05-09 | $0.00 derived: sum of 3 quarters · filed 2014-05-09 | $0.00 derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $0.00 derived: sum of 2 quarters · filed 2014-03-10 | $0.00 derived: sum of 3 quarters · filed 2014-03-10 | $0.00 10-K · filed 2014-03-10 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $0.00 10-Q · filed 2013-08-08 | ||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |